MedTrace Logo

Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)

NCT00133003 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2022

Last updated 2008-04-15

No results posted yet for this study

Summary

The purpose of this study is to determine whether there is any additional benefit from abciximab administration during percutaneous coronary intervention in patients presenting with acute coronary syndromes after pre-treatment with 600mg of clopidogrel.

Conditions

  • Coronary Disease
  • Angina, Unstable

Interventions

DRUG

Abciximab

0.25 mg/kg of body weight bolus, followed by a 0.125-microg/kg per minute \[maximum, 10 microg/min\] infusion for 12 hours, plus heparin, 70 U/kg of body weight

DRUG

Placebo

Placebo consist of placebo bolus and infusion of 12 hours (NaCl 0.9%), plus heparin bolus, 140 U/kg of body weight

Sponsors & Collaborators

  • Technical University of Munich

    collaborator OTHER

  • Deutsches Herzzentrum Muenchen

    lead OTHER

Principal Investigators

  • Albert Schomig, MD · Deutsches Herzzentrum Muenchen

  • Adnan Kastrati, MD · Deutsches Herzzentrum Muenchen

  • Peter B Berger, MD · Duke Clinical Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31
Primary Completion
2006-01-31
Completion
2006-01-31

Countries

  • Brazil
  • Germany
  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00133003 on ClinicalTrials.gov